Leverage Factor
| Project | Cost | Real world outcome | Outcome estimates | Economic value in Western terms | Leverage Factor |
|---|---|---|---|---|---|
| Malaria prevention and Artemesinin Combination Therapy treatment package (Solutions to the World's Biggest Problems, Bjorn Lomborg, 2007, pp. 325) | $500m/yr | 500k mostly child lives/yr | - | $1.3t | 2,600 |
| Indoor residual spraying (Priorities in Healthcare, The World Bank, 2006, pp. 75) | $5-18 | 1 DALY saved | - | $90k | 5,000 - 18,000 |
| Indoor residual spraying (Disease Control Priorities Project reports on the cost effectiveness of intervention) | $9-24 | 1 DALY saved | - | $90k | 4,000 - 10,000 |
| Intermitent prophylactic treatment during pregnancy (Disease Control Priorities Project reports on the cost effectiveness of intervention) | $2-11 | 1 DALY saved | Sub-Saharan Africa | $90k | 8,000 - 45,000 |
Prophylactic treatment during pregnancy is considered a special case, and so won't be incorporated into the overall Leverage Factor.
Leverage Factor
4,000 - 20,000